FY2025 · ended Dec 31, 2025 · Revenue $322.67M, +13.8% YoY · Filed Feb 27, 2026
Fulgent Genetics, Inc. (FLGT) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $322.7 million and a net loss of $60.5 million. Free cash flow was -$124.2 million. As of Jun 30, 2026 it held $551.3 million in cash and investments and $7.6 million in total debt.
Revenue (TTM)
$323.93M
+6.8% vs year-ago TTM
Net income (TTM)
$-84.38M
-65.4% vs year-ago TTM
Operating cash flow (TTM)
$-83.70M
-233.5% vs year-ago TTM
Free cash flow (TTM)
$-103.79M
-73.1% vs year-ago TTM
EPS (TTM)
$-2.80
-67.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
31.23M
+1.3% vs prior year
Net cash
$543.70M
as of Jun 30, 2026
Operating margin
-37.7%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- FLGT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- El Monte, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1674930
- Former names
- Fulgent Diagnostics, Inc. (until Jul 15, 2016)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $322.7M | $283.5M | $289.2M | $619.0M | $992.6M |
| Operating income | -$91.1M | -$73.9M | -$195.5M | $178.5M | $676.0M |
| Net income | -$60.5M | -$42.7M | -$167.8M | $143.4M | $507.4M |
| Operating cash flow | -$101.6M | $21.1M | $27.0M | $253.5M | $538.6M |
| Free cash flow | -$124.2M | -$19.3M | $4.8M | $234.7M | $514.8M |
| Total assets | $1.2B | $1.2B | $1.2B | $1.4B | $1.3B |
| Total liabilities | $106.8M | $90.8M | $102.0M | $116.2M | $112.8M |
| Stockholders' equity | $1.1B | $1.1B | $1.1B | $1.3B | $1.2B |
| Cash and investments | $705.3M | $625.5M | $521.0M | $406.2M | $649.9M |
| Total debt | $5.6M | $6.3M | $12.4M | $17.7M | $8.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Other events
|
Jun 2, 2026 | Jun 1, 2026 |
| 8-K |
Current report
Other events
|
May 21, 2026 | May 21, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 1, 2026 | Mar 31, 2026 |
All 668 Fulgent Genetics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.